NZ331299A - Antibody variants with reduced affinity for a cell-surface antigen - Google Patents

Antibody variants with reduced affinity for a cell-surface antigen

Info

Publication number
NZ331299A
NZ331299A NZ331299A NZ33129997A NZ331299A NZ 331299 A NZ331299 A NZ 331299A NZ 331299 A NZ331299 A NZ 331299A NZ 33129997 A NZ33129997 A NZ 33129997A NZ 331299 A NZ331299 A NZ 331299A
Authority
NZ
New Zealand
Prior art keywords
antibody
cell
surface antigen
reduced affinity
therapeutic
Prior art date
Application number
NZ331299A
Other languages
English (en)
Inventor
Herman Waldmann
Lisa Kim Gilliland
Masahide Tone
Mark Raymond Frewin
Louise Walsh
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation filed Critical Isis Innovation
Publication of NZ331299A publication Critical patent/NZ331299A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NZ331299A 1996-02-20 1997-02-20 Antibody variants with reduced affinity for a cell-surface antigen NZ331299A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9603507.6A GB9603507D0 (en) 1996-02-20 1996-02-20 Antibody variants
PCT/GB1997/000472 WO1997031024A1 (en) 1996-02-20 1997-02-20 Antibody variants

Publications (1)

Publication Number Publication Date
NZ331299A true NZ331299A (en) 2000-05-26

Family

ID=10789047

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ331299A NZ331299A (en) 1996-02-20 1997-02-20 Antibody variants with reduced affinity for a cell-surface antigen

Country Status (11)

Country Link
US (2) US20020048578A1 (enExample)
EP (1) EP0970127B1 (enExample)
JP (1) JP4574750B2 (enExample)
AT (1) ATE373016T1 (enExample)
AU (1) AU723366B2 (enExample)
CA (1) CA2246715C (enExample)
DE (1) DE69738138T2 (enExample)
ES (1) ES2294793T3 (enExample)
GB (1) GB9603507D0 (enExample)
NZ (1) NZ331299A (enExample)
WO (1) WO1997031024A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69621940T2 (de) * 1995-08-18 2003-01-16 Morphosys Ag Protein-/(poly)peptidbibliotheken
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
WO2000029584A1 (en) 1998-11-18 2000-05-25 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
AU2001293995B2 (en) * 2000-10-09 2005-10-13 Cytomx Therapeutics, Inc. Therapeutic antibodies
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
US20040109855A1 (en) * 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
EP1618891A1 (en) * 2003-03-31 2006-01-25 Kirin Beer Kabushiki Kaisha Method of inducing differentiation and proliferating regulatory t cell by anti-cd52 antibody and medicinal composition therefor
JP4972549B2 (ja) * 2004-05-19 2012-07-11 イムノコア リミテッド Ｔ細胞レセプターを改善する方法
EP2481424A1 (en) * 2005-03-19 2012-08-01 Medical Research Council Improvements in or relating to treatment and prevention of hepatitis C viral infections
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
EP2152300A4 (en) * 2007-05-16 2012-12-05 Sinomab Bioscience Ltd FUNCTIONAL HUMANIZATION OF COMPLEMENTARITY-REGULATING REGIONS
JP6035009B2 (ja) 2007-08-22 2016-11-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
BRPI1006141B8 (pt) 2009-01-12 2021-05-25 Cytomx Therapeutics Llc composições de anticorpo modificado, métodos para preparar e usar as mesmas
CA2753294A1 (en) 2009-02-23 2010-08-26 Cytomx Therapeutics, Inc. Proproteins and methods of use thereof
CN104231084B (zh) 2009-05-13 2019-04-23 基酶有限公司 抗人cd52免疫球蛋白
CN102449149B (zh) 2009-05-29 2014-04-23 莫佛塞斯公司 集合及其使用方法
JP6253986B2 (ja) 2010-11-19 2017-12-27 モルフォシス・アーゲー コレクション及びその使用方法
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
US9494597B2 (en) * 2012-04-02 2016-11-15 Ab Biosciences, Inc. Human control antibodies and uses therefor
RU2713121C2 (ru) 2012-04-27 2020-02-03 Сайтомкс Терапьютикс, Инк. Активируемые антитела, которые связываются с рецептором эпидермального фактора роста, и способы их применения
SG11201508358RA (en) 2013-04-09 2015-11-27 Boston Biomedical Inc 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
WO2015066279A2 (en) 2013-10-30 2015-05-07 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
US9737623B2 (en) 2013-12-11 2017-08-22 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
US20160120158A1 (en) * 2014-11-03 2016-05-05 The Johns Hopkins University Compositions and methods for the study and treatment of acute kidney injury
MX2017015618A (es) 2015-06-03 2018-08-15 Boston Biomedical Inc Composiciones que comprenden un inhibidor de la autorrenovación y diferenciación de células madre cancerosas y un agente inmunoterapéutico para su uso en el tratamiento del cáncer.
JP7106563B2 (ja) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー， インコーポレイテッド ナフトフラン誘導体、その調製、および使用方法
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
US12465637B2 (en) 2019-04-30 2025-11-11 Institute For Cancer Research Compositions and methods for modulation of antibody activity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU618989B2 (en) * 1988-02-12 1992-01-16 British Technology Group Limited Improvements in or relating to antibodies
US5846534A (en) * 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
US5858725A (en) * 1990-10-10 1999-01-12 Glaxo Wellcome Inc. Preparation of chimaeric antibodies using the recombinant PCR strategy
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ATE174515T1 (de) * 1991-10-15 1999-01-15 Btg Int Ltd Verwendung eines cdw52-spezifischen antikörpers zur behandlung von durch t-zellen vermittelten gelenkentzündungen
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method

Also Published As

Publication number Publication date
US20060018898A1 (en) 2006-01-26
CA2246715A1 (en) 1997-08-28
ES2294793T3 (es) 2008-04-01
WO1997031024A1 (en) 1997-08-28
CA2246715C (en) 2008-08-05
AU723366B2 (en) 2000-08-24
GB9603507D0 (en) 1996-04-17
US8440190B2 (en) 2013-05-14
EP0970127B1 (en) 2007-09-12
ATE373016T1 (de) 2007-09-15
AU1885197A (en) 1997-09-10
JP4574750B2 (ja) 2010-11-04
US20020048578A1 (en) 2002-04-25
JP2000506723A (ja) 2000-06-06
DE69738138D1 (de) 2007-10-25
EP0970127A1 (en) 2000-01-12
DE69738138T2 (de) 2008-06-05

Similar Documents

Publication Publication Date Title
NZ331299A (en) Antibody variants with reduced affinity for a cell-surface antigen
EP0854917A4 (en) NON-HUMAN TRANSGENIC ANIMALS WHICH MAY PRODUCE HETEROLOGOUS ANTIBODIES
EP0754225A4 (en) HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
MY109957A (en) Improved antibodies to plasmodium falciparum
EP0942959A4 (en) NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
IL97653A0 (en) Catalytic antibody components
DK0742795T3 (da) Immunstimulerende monoklonale antistoffer
NZ595450A (en) Antibodies to M-CSF
AU2821195A (en) Cross-reacting monoclonal antibodies specific for e-selectin and p-selectin
IL117942A (en) Antibody purification by low pH hydrophobic interaction chromatography
PL313260A1 (en) Monoclonal antibodies having properties making them able to cause apoptosis
ES2138102T3 (es) Procedimiento para la deteccion de antigeno urinario asociado a tumores.
ATE290597T1 (de) Monoklonale antikörper die die remyelinisierung des zentralnervensystems fördern
ATE133994T1 (de) An karzinoma assoziierte antigene und antikörper, die diese antigene erkennen
WO1991010735A3 (fr) Recepteur humain de la tsh. sequence codant pour ce recepteur
DE3850993D1 (de) Monoklonaler Antikörper spezifisch gegen humane Pankreas-Phospholipase-A2.
IL133881A0 (en) Decreased fat adsorption with an anti-lipase antibody
ES2173879T3 (es) Procedimiento para la preparacion de conjugados a base de un participe especifico en la fijacion y de una proteina que contiene hidratos de carbono
DE59611293D1 (de) Protein mit dnase-aktivität
AU2001249546A1 (en) Methods for treating disease with antibodies to cxcr3
AU1997897A (en) Nucleic acid-bound polypeptide, method of producing nucleic acid-bound polypeptide, and immunoassay using the polypeptide
NZ314010A (en) A method of targeting intracellular binding proteins using a lipidized antibody
IT8821547A0 (it) Metodo immunologico per la determinazione di anticorpi anti antigeni di microorganismi, mediante anticorpi antiidiotipo e mezzi adatti allo scopo.
FI961439L (fi) Menetelmä terapeuttisesti käyttökelpoisen vasta-aineen tai vasta-ainefragmentin valmistamiseksi
FI940684L (fi) Menetelmä Streptococcus suis -bakteerin adhesiiniproteiinin ja sen vasta-aineen valmistamiseksi

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired